ArticleFrontiers in oncology2021

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer.

Yifan Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.